Corvus Pharmaceuticals Files 8-K
Ticker: CRVS · Form: 8-K · Filed: May 8, 2025 · CIK: 1626971
| Field | Detail |
|---|---|
| Company | Corvus Pharmaceuticals, Inc. (CRVS) |
| Form Type | 8-K |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financials, operations
Related Tickers: CRVS
TL;DR
CRVS filed an 8-K on May 8th, check financials and operations.
AI Summary
Corvus Pharmaceuticals, Inc. filed an 8-K on May 8, 2025, reporting on results of operations, financial condition, and other events. The filing includes financial statements and exhibits, with the company's principal executive offices located in South San Francisco, California.
Why It Matters
This 8-K filing provides an update on Corvus Pharmaceuticals' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting routine operational and financial information, not indicating any immediate significant risks.
Key Players & Entities
- Corvus Pharmaceuticals, Inc. (company) — Registrant
- May 8, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Address of principal executive offices
FAQ
What specific items are being reported in this 8-K filing?
This 8-K filing reports on Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was this 8-K filing submitted?
This 8-K filing was filed as of May 8, 2025.
What is the principal executive office address for Corvus Pharmaceuticals, Inc.?
The address of the principal executive offices is 901 Gateway Boulevard, Third Floor, South San Francisco, California 94080.
What is the Standard Industrial Classification code for Corvus Pharmaceuticals, Inc.?
The Standard Industrial Classification code for Corvus Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Corvus Pharmaceuticals, Inc.?
The fiscal year end for Corvus Pharmaceuticals, Inc. is December 31 (1231).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding Corvus Pharmaceuticals, Inc. (CRVS).